HemAryo (eptacog alfa (activated))
- Region
- 🇪🇺 EU
- Active substance
- eptacog alfa (activated)
- Company
- UGA Biopharma
- Status
- Application withdrawn
- Therapeutic area
- Hemophilia A; Hemophilia B; Factor VII Deficiency
- Application
- EMEA/H/C/005547
- ATC
- B02BD08
- Official record
- www.ema.europa.eu
Indication
Treatment of bleeding episodes and for the prevention of bleeding.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 NovoSeven Authorised · Novo Nordisk A/S
Follow HemAryo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.